Investment Firm Maytree Bought Over $11 Million in AXTI. Is the Stock a Buy?

Maytree Asset Management established a new 682,299-share position in AXT (AXTI) in Q4, an estimated $11.16 million stake that represented roughly 8.27% of the firm's 13F reportable AUM and pushed AXT into its top-five holdings. AXT shares were $20.94 on Feb. 2, 2026 (up ~911.6% year-over-year), with market cap ~$1.15 billion, TTM revenue $90.39 million and a TTM net loss of $22.98 million; Q3 revenue improved to $28 million (from $23.6 million) while operating losses narrowed to $1.1 million. The buy signals institutional bullishness tied to AI-driven demand for semiconductor substrates, but the stock trades at an elevated ~9x price-to-sales multiple and remains unprofitable, suggesting cautious positioning for fundamental investors.

Analysis

Market structure: Maytree’s new 8.3% stake in AXTI (market cap $1.15bn, TTM revenue $90m) signals concentrated conviction in semiconductor substrates and photonics; direct winners are AXT and upstream suppliers of indium/gallium/germanium while general-purpose CPU suppliers gain less incremental demand. The stock’s 911% YTD move and P/S ~9 compress pricing discipline — expect elevated options IV, tighter small‑cap liquidity, and upward pressure on specialty material commodity prices while broader bond markets see only marginal risk‑free repricing.

Risk assessment: Immediate (days) risk is momentum unwind — intraday spikes can produce 20–40% retracements; short term (weeks–months) the key tail risks are China export controls, a single large customer cutback, or a commodity input shock that can blow out gross margins. Long term (3–24 months) upside requires sustained AI/photonics design wins and margin expansion; hidden dependency: AXT’s revenue mix and OEM qualification cycles create lumpy bookings that can amplify quarter‑to‑quarter volatility. Near catalysts: upcoming quarterly results, design-win announcements, and any changes in US/China trade policy within 30–90 days.

Trade implications: Size positions small (1–2% NAV) and prefer volatility‑defined instruments: buy Jan‑2027 call spreads (25Δ buy / 10Δ sell) or cash on pullbacks to $12–$15 (50–60% retrace) with a $14 stop; target 12‑month upside to $35 if AI demand remains strong. Construct pair trades to isolate idiosyncratic risk: long AXTI vs short INTC (equal dollar) for 6–12 months to hedge cyclicality, and trim oversized NVDA exposure (>5% NAV) to redeploy into substrate/materials exposure on weakness.

Contrarian angles: Consensus assumes AI hardware growth is permanent and linear — that ignores customer concentration and multi‑quarter qualification lags; valuation implies tripling revenue without current profitability, which is aggressive. The market may be over‑rewarding speculative wins; historical parallels (optics/laser supplier spikes in 2015–2017) show rapid reversals when end‑market inventories normalize, so require explicit stop/size discipline and confirmatory fundamental catalysts before scaling.

Key Decisions for Investors

• Establish a 1.5% NAV long position in AXTI on a pullback to $12–$15 (approx. 40–60% retrace from $20.94). Set hard stop at $14 and target $35 within 12 months; reassess if revenue guidance fails to grow quarter‑over‑quarter.
• If no pullback occurs, allocate 0.5% NAV to a Jan‑2027 call spread (buy ~25Δ call, sell ~10Δ call) to express upside while capping premium; close if AXTI > +50% or IV falls >30% from entry.
• Implement a 1% NAV pair trade (Long AXTI / Short INTC equal dollars) for 6–12 months to hedge macro beta; exit the pair if the pair P&L moves against you by 25% or if AXTI outperforms INTC by 50%.
• If NVDA exposure >5% NAV, trim by 1–2% and redeploy proceeds into semiconductor materials/photonic exposures (AXTI or sector ETF) to diversify away from compute concentrators; execute within next 30 trading days.